- Clario's third annual ESG report for the calendar year 2023
highlights advancements in responsible artificial intelligence
(AI), employee program investments, and ambitious science-based
sustainability targets.
- The report highlights initiatives like the C.O.R.E.
onboarding program for new hires, leadership training through the
Manager Essentials Program, and our commitment to ethical data use
and privacy as embodied in our AI responsible use
principles.
- Clario commits to achieving net-zero emissions by 2045, with
interim targets developed for validation by the Science-Based
Targets initiative and achieving ISO 14001:2015 certification for
efficient resource use and waste reduction.
PHILADELPHIA, Aug. 20, 2024 /PRNewswire/ -- Clario,
a healthcare research technology company that delivers leading
endpoint technology solutions for clinical trials, today
released its third annual Environmental, Social, and Governance
(ESG) report for the calendar year 2023. Key aspects of this report
include the development of principles to govern the company's
responsible use of artificial intelligence (AI), further
investments in employee development programs, and a submission for
validation of science-based targets essential to its sustainable
growth and ethical business operations.
![Clario Clario](https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg)
"At Clario, science and quality data are the backbone of every
technology, product, and service we provide to our customers,"
said Chris Fikry, Chief Executive
Officer. "Reflecting on our third ESG report, I'm proud of the
progress we continue to make. This report reaffirms our tireless
commitment to responsibly advancing technologies, investing in our
employees, and ambitious climate action. Our mission to help our
customers deliver better living through innovation shines through
in these efforts."
Notable highlights from the report include:
Responsibly advancing technologies: Last year, Clario
reinforced its commitment to ethical AI by instituting five
organizational principles to govern the company's responsible use
of AI. Since 2018, Clario has leveraged AI solutions across our
technology platform to expedite clinical data collection, decrease
data variability, and strengthen patient privacy thereby increasing
the quality and precision of clinical data capture. By
ethically developing and implementing AI, Clario is advancing
clinical trial endpoint analysis and enhancing the sponsor
experience.
Investments in employee programs: The Clario Onboarding
Readiness Experience (C.O.R.E.) program was a significant
initiative that started in 2023 and the purpose of which is to
welcome all new hires and immerse them in the company's culture,
values, and goals. The C.O.R.E. program fosters a sense of
belonging and promotes team cohesion. Additionally, the Manager
Essentials Program (MEP) made great strides in 2023, with newly
appointed people managers participating globally in leadership
training focused on culture, engagement, vision, strategy, and
coaching. These employee programs enhance a culture of leadership
and foster inclusiveness.
Science-based targets: In 2023, Clario aligned its
sustainability goals with the Paris Climate Accord's "well-below
2.0-degree" trajectory. Clario submitted ambitious emissions
reduction targets for validation by the Science-Based Targets
initiative (SBTi), aiming for net-zero emissions by 2045. Clario
achieved a significant reduction in direct greenhouse gas (GHG)
emissions in 2023 by implementing strategic office consolidations
for remote work flexibility, and by working with key value chain
stakeholders. These efforts contributed to a 20% reduction year
over year in the company's GHG emissions. Additionally, Clario's
Estenfeld, Germany facilities
achieved ISO 14001:2015 certification in acknowledgment of the
facilities' dedication to efficient resource use and waste
reduction.
"Setting these targets is crucial for driving innovation and
creating value while addressing environmental impacts," said
Ellen Street, EVP, Digital
Physiology and ESG Executive Sponsor. "Our commitment to
combating climate change is to lead by example and work towards a
sustainable future for our customers and communities. Achieving ISO
14001:2015 certification supports our dedication to responsible
practices and continuous improvement, which ultimately benefits our
customers and their patients worldwide."
To access Clario's third annual Environmental, Social, and
Governance (ESG) report, go to Clario.com.
About Clario
Clario is a leading healthcare research and technology company
that generates high quality clinical evidence for our
pharmaceutical, biotech, and medical device partners. We offer
comprehensive evidence generation solutions that combine eCOA,
cardiac solutions, medical imaging, precision motion, and
respiratory endpoints.
Since our founding more than 50 years ago, Clario has delivered
deep scientific expertise and broad endpoint technologies to help
transform lives around the world. Our endpoint data solutions have
supported clinical trials over 26,000 times in more than 100
countries. Our global team of science, technology, and operational
experts have supported over 60% of all FDA new drug approvals since
2012.
For more information, go to Clario.com or follow us on
LinkedIn.
Contact Information
media@clario.com
Logo -
https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clario-publishes-third-annual-esg-report-reaffirms-commitment-to-ethical-ai-workforce-investment-and-sustainability-targets-302225328.html